What Xcell Biosciences does

Xcell Biosciences is a privately held San Francisco-based developer and manufacturer of cell therapy manufacturing platforms founded circa 2015 by CEO Brian Feth, with a wholly owned Australian subsidiary in Southbank, Melbourne. The company sells the AVATAR platform, a portfolio of three integrated instruments designed to bring physiologically relevant tumor microenvironment (TME) control — specifically oxygen and pressure — into cell therapy workflows to improve potency, persistence, and predictability for solid tumor therapies. AVATAR ODYSSEY is a small-scale benchtop instrument for R&D and process development with over 200 units sold globally; AVATAR FOUNDRY is a closed, automated GMP manufacturing platform currently deployed at 14 beta clinical sites with patient treatments expected in 2025-2026; and AVATAR AI is a label-free, electrical impedance-based potency assessment system that uses machine learning to generate real-time killing curves and predict therapeutic potency.

The company's core technology addresses the unsolved problem that cell therapies for solid tumors exhibit poor potency and early exhaustion in hostile TMEs, and that manufacturing workflows for blood-based cancers remain too long (10-14 days) and supply-constrained to serve addressable patient populations. AVATAR claims a demonstrated 70% improvement in CAR-T cytotoxicity in TME conditions and the ability to shorten blood-based manufacturing workflows to 1-3 days through metabolic conditioning. Validated customers include Bluebird Bio (using AVATAR as a potency release assay for the betibeglogene autotemcel gene therapy), Bayer, Kite Pharma, Novartis, Calibr/Scripps, Amplify Bio, University of Pennsylvania, and Royal Perth Hospital; the platform is also referenced at institutions in approximately 35 countries.

Xcell generates revenue primarily through hardware sales of ODYSSEY research systems and FOUNDRY GMP systems, supplemented by installation, training, consumables, and service contracts under multi-year enterprise procurement arrangements. Pricing is quote-based and not publicly disclosed. The go-to-market is direct enterprise sales targeting pharmaceutical and biotech cell therapy developers plus academic medical centers, supported by conference presence at AACR and Advanced Therapies Week and a thought leadership program featuring CEO Brian Feth and CTO Shannon Eaker. Strategic partnerships with LabCorp (strategic investor and board observer), Thermo Fisher (instrument integration), Cellular Origins (robotics), GermFree (portable clean rooms), and Culture Biosciences (AI/ML integration) collectively define a decentralized point-of-care manufacturing ecosystem intended to enable hospital-based cell therapy production closer to patients.

Name

Xcell Biosciences

Legal name

Xcell Biosciences Inc.

Website

https://xcellbio.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Xcell Biosciences develops and manufactures the AVATAR platform — integrated ODYSSEY, FOUNDRY, and AI instruments that apply physiologically relevant oxygen and pressure control to improve cell therapy potency, persistence, and manufacturing for pharmaceutical, biotech, and academic customers.

Ownership category

akta.pro rank

Product category

Cell Therapy Manufacturing Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Translational Medicine & Biomarkers (HLAIALAF), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)

Keywords

• Cell therapy manufacturing
• Tumor microenvironment control
• GMP bioprocessing instruments
• Potency assay platforms
• Cell therapy instrumentation

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. AVATAR ODYSSEY (Research Instruments): Sale of small-scale benchtop instruments for R&D and process development. Over 200 systems sold to pharmaceutical companies, biotech firms, and academic institutions. Platform used for drug screening, stem cell differentiation, and immune cell process development.
2. AVATAR FOUNDRY (GMP Manufacturing Systems): Sale and deployment of GMP-grade automated manufacturing systems for clinical and commercial cell therapy production. 14 beta systems deployed at clinical sites with patient treatments expected beginning 2025. Instrument sales supplemented by consumables and service contracts.
3. AVATAR AI (Potency Assay Platform): Generational upgrade to the ODYSSEY system with integrated electrical impedance-based live-cell analysis. Revenue derived from instrument sales and potential per-use consumable/assay consumables as platform scales into manufacturing release workflows.
4. Service, Installation & Support: Installation, commissioning, training, and ongoing technical support for ODYSSEY and FOUNDRY systems. Dedicated process development team supports customers with workflow validation and optimization.
5. AI/ML-Driven Process Optimization Services: Integration of AI and machine learning into manufacturing workflows with Culture Biosciences partnership, enabling real-time data analysis and process optimization for cell therapies — potentially generating data services revenue as platform matures.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Xcell Biosciences designs, manufactures, and sells the AVATAR platform — integrated instruments that replicate physiologically relevant tumor microenvironments (oxygen and pressure control) to improve potency, persistence, and predictability of cell therapies. The portfolio spans AVATAR ODYSSEY for small-scale R&D and process development, AVATAR FOUNDRY for automated GMP clinical and commercial manufacturing, and AVATAR AI for real-time label-free potency assessment via electrical impedance and machine learning. Customers include pharmaceutical and biotech companies developing CAR-T, TCR-T, and TIL therapies plus leading academic medical centers.

Product overview

Xcell Biosciences offers the AVATAR platform, a unified portfolio of cell therapy manufacturing technologies consisting of three integrated products: AVATAR ODYSSEY for small-scale R&D and process development, AVATAR FOUNDRY for GMP clinical and commercial-scale manufacturing, and AVATAR AI for potency assessment and AI/ML-driven optimization. The platform provides microenvironment control through physiologic oxygen and pressure conditions to improve cell therapy potency, persistence, and predictability for solid tumor applications.

Differentiator

Problem solved

Functional benefit

Brands

• AVATAR: Umbrella trademark for the company's technology platform. AVATAR ODYSSEY is the small-scale R&D/process development system; AVATAR FOUNDRY is the GMP clinical and commercial-scale manufacturing system; AVATAR AI is the machine learning-powered potency screening and real-time analysis platform.
• AVATAR ODYSSEY
• AVATAR FOUNDRY
• AVATAR AI

Products and services

• AVATAR ODYSSEY Small-scale benchtop R&D and process development instrument that uses precise oxygen and pressure control to refine cell activation, expansion, and phenotype optimization in cost-effective workflows. Used by pharma, biotech, and academic researchers for drug screening, stem cell differentiation, immune cell process development, and identifying optimal environmental parameters that drive maximum potency.
• AVATAR FOUNDRY Automated, closed, GMP-grade manufacturing system for clinical and commercial-scale cell therapy production. Brings metabolic conditioning into clinical and commercial production with identical environmental profiles to AVATAR ODYSSEY, reducing technical transfer risk and accelerating translation from lab to clinic. Designed for decentralized point-of-care manufacturing with drop-in GMP compatibility.
• AVATAR AI Potency assessment platform using electrical impedance sensing in a 96-well plate format to generate real-time, label-free killing curves under physiologically relevant conditions. Machine learning models analyze killing kinetics to enable rapid potency assessment, deep therapeutic performance insights, and predictive release decisions for cell therapy manufacturing.

Quantifiable outcome

• AVATAR-expanded CAR T cells demonstrated 70% improvement in cytotoxicity in TME conditions compared to conventionally cultured cells
• +3 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature7 records

Partnerships

Six partnerships are on record, tiered core, supporting and flagship.

• Culture BiosciencescoreTechnology or Integration · 9 December 2025Collaboration to integrate AI and machine learning into the Xcellbio AVATAR Foundry system for cell therapy development and manufacturing. Partnership aims to enable real-time data analysis and process optimization, potentially improving clinical outcomes through predictive analytics integrated directly into the manufacturing workflow.
• Thermo Fisher ScientificcoreTechnology or Integration · 1 January 2025Partnership to link AVATAR FOUNDRY system with Thermo Fisher instruments (upstream and downstream) to create an integrated, automated cell therapy manufacturing workflow. Goal is to realize the vision of decentralized point-of-care manufacturing through seamless instrument interoperability.
• Cellular OriginscoreTechnology or Integration · 1 January 2025Partnership with Cellular Origins for robotics integration to automate and link cell therapy manufacturing workflows. Combined with AVATAR FOUNDRY to create fully automated manufacturing systems suitable for deployment in hospital settings.
• GermFreesupportingImplementation/ SI/ Consulting Partner · 1 January 2025Partnership with GermFree to integrate AVATAR FOUNDRY into portable or decentralized clean room facilities, enabling hospital-based cell therapy manufacturing closer to patients. Complements point-of-care distribution strategy.
• Royal Perth HospitalcoreStrategic or Co-development Partner · 1 January 2025Partnership with Royal Perth Hospital and Xcell Bio Australia for rapid TIL (tumor-infiltrating lymphocyte) therapy manufacturing using AVATAR platform. Australian hospital exemption pathway enables patient treatment of metastatic melanoma. Model to be replicated across other Australian hospitals.
• LabCorpflagshipStrategic or Co-development Partner · 1 April 2024Expanded research collaboration involving increased investment and strategic partnership, including beta access to the AVATAR Foundry GMP system for cell therapy manufacturing. LabCorp serves as observer on Xcell Biosciences board of directors. Companies jointly present collaboration results at AACR conference, focusing on cell and gene therapy innovations targeting solid tumors with improved potency and efficiency.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/XcellBio
• LinkedInlinkedin.com/company/xcell-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xcell Biosciences